1. Alderson P, Green S, Higgins JPT (eds) (2003) Cochrane Reviewers' Handbook 4.2.2. Chichester, UK, Ltd: John Wiley & Sons, Available at
http://www.cochrane.org/resources/handbook/hbook.htm
(accessed 31 January 2005)
2. Bernard-Marty C, Cardoso F, Piccart MJ (2003) Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer 39: 1978–1989
3. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ (2002) Doxorubicin and paclitaxel vs doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: EORTC 10961. J Clin Oncol 20(14): 3114–3121
4. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta RL (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17(8): 2355–2364
5. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre M, Delozier T, Culine S, Dohollou N, Suissa J, Samak R (2001) 6 cycles of epirubicin/docetaxel (ET) vs 6 cycles of 5FU epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment. Proceedings of the American Society of Clinical Oncology Abstract 163, Available at
http://www.asco.org/ac/1,1003,_12-002636-00_18-0010-00_19-00163,00.asp
(accessed 15 September 2004)